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SummAry – diabetic polyneuropathy occurs in around 50% of diabetic patients. its pathop-
hysiological mechanism is not completely clarified and major occurrences boil down to the change 
in neural phenotype and vasa nervorum. As glucose neurotoxicity has been suggested by plenty of 
evidence, the aim of the study was to assess the effect of glycemia on the severity of diabetic pol-
yneuropathy. Considering that some practical experiences point to serious complications in patients 
suffering from diabetes of shorter duration, another aim was to assess the effect of diabetes duration 
on the severity of related neuropathy. Clinical and electromyoneurographic examinations were per-
formed in 100 patients with diabetic polyneuropathy free from any laboratory signs of renal failure. 
The effect of hbA1c value and duration of disease on clinical symptoms, signs and electrophysiolo-
gical indicators of polyneuropathy was analyzed. Study results indicated that 78% of patients with 
diabetic polyneuropathy did not have well-regulated glycemia. diabetes duration was associated 
with a growing number of sensory symptoms, among which the sensation of pain similar to electric 
shock was present in 63% of patients. in addition, it also had negative impact on the sensory and 
motor nerve conduction velocity. hbA1c influenced the whole range of electrophysiological indica-
tors of diabetic polyneuropathy.
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Introduction
it is known that there is a multiple (up to four 
times) increase of glucose concentration in the blood 
of patients with diabetes mellitus (dm), which is 
then associated with glucose neurotoxicity. recent 
studies show that diabetic neuropathy will begin to 
develop at significantly lower levels of glycemia than 
it was thought previously1. The understanding of the 
pathophysiological activities in the neurons of diabet-
ic patients gives way to new possibilities of therapeutic 
interventions to ensure better quality of life for these 
patients. The example can be found in the proof from 
animal testing of the effect of poly adenosine ribose 
polymerase (PArP) inhibitors on the control of the 
motor and sensory neural fiber velocity reduction2, 
as well as the use of inhibition of the 12/15 lipoxy-
genase mediating in the pathological metabolism of 
amino acids during nitrous stress induced by hyper-
glycemia3. The biomarkers are used that correlate to 
clinical presentation of polyneuropathy and allow for 
monitoring its progression, such as increased level 
of γ-glutamyltransferase (ggt) and nitrates5,6. The 
pathogenesis of diabetic neuropathy is still controver-
sial and not completely understood. multiple trigger-
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ing factors are mentioned, such as metabolic, vascu-
lar or autoimmune disorders, oxidation and nitrous 
stress, as well as deficiency of neurohumoral growth 
factors5,6. Prolonged stress hyperglycemia in patients 
with ischemic stroke increases even the mortality rate 
of nondiabetic patients7. The protective activity of the 
blood-brain barrier is absent on peripheral nerves, and 
the abnormally high level of the inserted insulin-de-
pendent intracellular glucose activates various meta-
bolic paths that damage the myelin and axon and re-
sult in neuron degeneration6,8,9. This leads to complete 
breakdown of neuron function, loss of the protective 
function of senses, trauma insensitivity, and poorly 
treated wounds resulting in amputations. hyperg-
lycemia damages the microcirculation structure and 
function, as well as the blood-brain barrier, which 
results in ischemia10,11. The toxicity of glucose leads 
to damage to axon regeneration, ruins the excitability 
and conduction of neural impulses, and generates pain 
of the allodynia or hyperalgesia type6. neuropathic 
pain demands treatment with antidepressants and an-
ticonvulsants. Sometimes, poly-pharmacotherapy is 
needed12,13. it is known that the current blood glucose 
level does not reflect the constant value of glycemia 
that can be responsible for the pathophysiological pro-
cesses. The value of glycosylated hemoglobin is consid-
ered to be a good indicator of the average blood sugar 
levels. it is recommended to maintain it at <6.5% by 
therapeutic measures. We estimated the effect of he-
moglobin A1c (hbA1c) values on clinical and electro-
physiological indicators of polyneuropathy in dm pa-
tients. Since, according to some studies, hbA1c does 
not always correlate with the level of polyneuropathy, 
it was also investigated whether the duration of dm 
contributed to the accumulation of peripheral neu-
rologic damage. it was considered interesting since 
there is no unique attitude in the literature towards 
the impact of dm duration on the manifestation and 
intensity of electrophysiological and clinical signs of 
polyneuropathy15-17. 
Patients and Methods
The study included 100 patients with type 2 dm 
treated at diabetes Center, Vukovar general hospital, 
from January to July 2009. There were 59 women and 
41 men, average age 61 (range, 29-75) years and suffer-
ing from dm for 2 to 35 (average, 11) years. Patients 
with signs of impaired renal function, determined by 
increased laboratory values of creatinine clearance, 
urea and creatinine, patients regularly taking alcohol 
drinks, those suffering from systemic and malignant 
diseases, and patients with clinical and electrophysi-
ological signs of compressive mononeuropathies (e.g., 
carpal canal syndrome) were excluded. 
Patient hbA1c value was recorded and then each 
patient was classified according to glycemia regula-
tion as measured by hbA1c into one of the following 
groups: “good” if hbA1c <6.5%, “acceptable” if hbA1c 
≤7.0%, and “poor” if hbA1c >7.0%. The hbA1c values 
obtained by the method of microcolon determination 
were taken as reference values1.
The existence of clinical symptoms of polyneurop-
athy that were integrated and evaluated by use of the 
neuropathy total Symptom Score (ntSS-6), a scale 
usually employed for this purpose, was recorded in all 
study patients. The existence of 6 sensory symptoms 
was recorded, adding one point for the existence of a 
single symptom (up to a maximum of 6 points): deep 
pressuring, kneading pain; burning pain in feet and 
legs; pinching and pricking pain; being benumbed; 
loss of senses in legs (‘’numbness’’); sudden harsh pain 
resembling electric shocks that come in waves lasting 
for a couple of seconds to a minute; hypersensitivity of 
legs to touch or when the legs touch the ground while 
walking.
Clinical signs of polyneuropathy were diagnosed 
in all patients: crude muscular strength (CmS) in legs 
and arms, trophics of feet and hand muscles, muscle-
tendon reflex (mtr), touch sensation in feet and low-
er legs as well as in hands and forearms, and vibration 
detection by means of tuning fork19. 
All patients underwent detection electromyography 
(emg) and neurographic analysis including measure-
ment of conduction velocity as the so-called “gold stan-
dard” for assessment of polyneuropathy (conduction 
velocity of motor fibers of ulnar nerve, median nerve, 
deep peroneal nerve, tibial nerve, conduction velocity 
of sensory fibers of ulnar nerve, median nerve, sural 
nerve), determination of distal latency, minimal latency 
of f-wave in legs and arms, as well as the amplitudes 
of sensory potentials and muscular response20,21. All 
patients were examined by the Synergy model iSO-
1000VA electromyoneurography (emng) instrument. 
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detection electromyography was carried out by use of 
pin-electrodes. The degree of polyneuropathy was as-
sessed according to the degree of denervation in mus-
cles of feet and lower legs as well as of hands and fore-
arms. mildly reduced pattern with milder reduction in 
motoneurons was designated as mild polyneuropathy, 
the pattern with moderate reduction in motoneurons 
was designated as moderate polyneuropathy, whereas 
the pattern with severe reduction was designated as se-
vere polyneuropathy. neurographic analyses were per-
formed by use of standard techniques. The mean tem-
perature of the room in which the electrophysiologic 
analysis was conducted was 23 ºC. Skin temperature in 
patient feet ranged from 26 ºC to 28 ºC, and in hands 
from 30 ºC to 32 ºC.
each patient was given the information form ex-
plaining the procedure and the informed consent 
form to sign, in line with the principles and standards 
of good Clinical Practice, which includes assurance 
of personal integrity and welfare of patients in accor-
dance with the declaration of helsinki.  
Statistical analysis was carried out using the Sta-
tistica for Windows, version 6.0 (StatSoft, inc. tulsa, 
OK) statistical package. for description of continuous 
variables, arithmetic mean, standard deviation and 
range were used if variables were of normal range or 
median, and otherwise, interquartile range and range. 
Categorical variables were presented as frequency (%). 
The χ2-test was used to compare categorical variables 
among the groups. to assess the correlation between 
specific variables, regression analysis (linear, Spear-
man’s rank Correlation) was applied, i.e. χ2-test 
depending on the type of specific variables. dis-
crimination multivariate analysis by use of step-added 
variables (forward stepwise) was used for identification 
of independent predictors of polyneuropathy as well as 
electrophysiological parameters that best represented 
differentiation between polyneuropathy subgroups by 
the degree of severity. The level of statistical signifi-
cance was set at P<0.05.
Results
Three-quarters (78%) of our patients had poorly 
regulated glycemia with hbA1c values over 7%; 16% 
had acceptably regulated glycemia with hbA1c less 
than or exactly 7%; and only 6% had well regulated 
glycemia with hbA1c less than 6.5%. 
The most common clinical symptom of sudden 
harsh pain resembling electric shocks was recorded in 
63% of study patients; 57% of patients complained of 
annealing pain in legs, whereas deep pressuring pain 
of the allodynia type was recorded in the lowest per-
centage of patients (36%). figure 1 shows the preva-
lence of clinical symptoms of polyneuropathy in our 
patients according to ntSS-6. 
The most prominent clinical sign was lowered or 
absent sensation of vibration (81%), followed by low-
ered or absent reflex of Achilles tendon (rAt) in 
legs (69%), whereas lowered crude muscle strength 
in arms was the least common, recorded in 17% of 
cases (fig. 2).
Fig. 1. Prevalence of individual clinical symptoms of poly-
neuropathy in patients with diabetes mellitus according to 
NTSS-6.
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Fig. 2. Prevalence of clinical signs of polyneuropathy in pa-
tients with diabetes mellitus.
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The duration of dm was found to significantly 
influence the severity of denervation detected in the 
muscles of arms and legs. table 1 shows the severity 
of polyneuropathy to have increased with longer du-
ration of diabetes (P<0.0005); 25 patients with mild 
polyneuropathy and low level of denervation had an 
average diabetes duration of 8 years (7.93), whereas in 
30 patients the development of severe polyneuropa-
thy characterized by severe denervation took 16 (15.9) 
years. The signs of moderate polyneuropathy charac-
terized by moderate loss of motoneurons were present 
in almost half of our patients (45%), 30% had severe 
polyneuropathy with a higher grade of axon damage, 
and 25% had mild polyneuropathy.
A significant link was found between the duration 
of dm and the intensity of clinical symptoms and 
signs of polyneuropathy; according to the ntSS-6 
scale, a higher sum of sensory symptoms was recorded 
in patients with longer duration of dm. They experi-
enced higher hypersensitivity to touch in feet, lowered 
gmS of arms and legs, lower or absent rAt reflex, 
lower sense of touch and vibration compared to the 
patients with shorter dm duration. elderly patients 
were not recorded with a significantly higher sum of 
sensory symptoms (ntSS-6) compared to young pa-
tients. 
The patients with longer dm duration had slower 
conduction velocity of motor fibers in arms and legs, 
i.e. motor nerve conduction velocity (mnCV) of ul-
nar nerve, peroneal nerve and tibial nerve, as well as 
lower sensory nerve conduction velocity (SnCV) of 
median nerve in arms and of sural nerve in legs. Al-
most all indicators tested in relation to dm duration 
yielded a mild biologic correlation (table 2).
Patients with higher hbA1c values suffered from 
severe polyneuropathy assessed according to the se-
verity of denervation or axon damage in arms and 
legs; in patients suffering from mild polyneuropathy 
(mild level of denervation), moderate polyneuropathy 
(moderate level of denervation) and severe polyneu-
ropathy, the mean hbA1c value was 7.79%, 8.43% and 
9.09%, respectively. 
table 3 shows that patients with higher levels of 
hbA1c also had significantly worse neurographic pa-
rameters of diabetes polyneuropathy: they had lower 
conduction velocity of motor fibers of peroneal and 
Table 1. Classification of patients according to duration of 
disease and severity of diabetic polyneuropathy
degree of polyneuropathy
(according to the degree 
of denervation detected in 











χ±Sd for disease duration 11.15±7.48 100
P<0.0005
Table 2. Influence of disease duration on electrophysiological parameters in patients with diabetic polyneu-
ropathy (N=100)
total
patients Spearman t (n-2) P value
disease duration and polyneuropathy 
– degree of denervation 100 0.389 4.169 0.000
disease duration and mnCV of ulnar nerve 100 -0.252 -2.575 0.012
disease duration and mnCV of peroneal nerve 100 -0.286 -2,960 0.003
disease duration and mnCV of tibial nerve 100 -0.290 -3.110 0.002
disease duration and SnCV of median nerve 100 -0.214 -2.166 0.033
disease duration and SnCV of sural nerve 100 -0.213 -2.156 0.033
disease duration and peroneal nerve distal latency 100 -0.279 -2.877 0.004
disease duration and amplitude of peroneal nerve
evoked muscle response 100 -0.369 -3.931 0.000
mnCV = motor nerve conduction velocity; SnCV = sensory nerve conduction velocity; P<0.05
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tibial nerve (mnCV), and of sensory fibers (SnCV) 
of ulnar and sural nerve compared to dm patients 
with lower hbA1c. Patients with higher levels of 
hbA1c had longer distal latency of peroneal, ulnar and 
tibial nerves, and lower amplitude of evoked mus-
cle response after stimulation of peroneal and tibial 
nerve, as well as lower amplitudes of the compound 
motor action potential (CmAP) after stimulation of 
peroneal and tibial nerves. Patients with higher levels 
of hbA1c had longer wave latencies in arms and legs, 
and lower amplitude of evoked sensory potential after 
stimulation of fibers of ulnar nerve. 
table 4 shows the most sensitive electrophysi-
ological parameters, which were significantly worse 
in the groups of patients with poorly regulated glyce-
mia (hbA1c ≥7%): mnCV and SnCV of ulnar nerve, 
SnCV of sural nerve and middle latencies of f wave 
in arms and legs. for example: the middle SnCV of 
sural nerve in the group with best regulated hbA1c 
was 39.45 m/s; in the group with acceptably regulated 
hbA1c it was slower than 34.09 m/s, and in the group 
of poorly regulated diabetes with hbA1c >7% it was 
slowest, 29.74 m/s (P=0.02). 
Discussion
in three-quarters of our patients, glycemia was 
not well regulated. This result is not in discrepancy 
with the european (Code 2 – The cost of diabetes in 
europe) and American data (nhAneS, national 
health and nutrition examination Survey), accord-
ing to which almost two-thirds of patients do not 
reach the target level of hbA1c of 6.5% or less22. 
The findings of the most prominent symptoms of 
polyneuropathy in patients with dm are different, 
making it difficult to determine its diagnosis, severity 
and progression. According to rubino et al., the most 
common clinical sign of polyneuropathy in patients 
with dm was the feeling of pricking, as recorded 
in france, italy and Spain; in great britain, numb-
Table 3. Influence of glycosylated hemoglobin values (HbA1c) on electrophysiological parameters in diabetic 
patients (N=100)
total 
patients Spearman t (n-2) P value
hbA1c and ulnar nerve distal latency 100 -0.237 -2.414 0.017
hbA1c and mnCV of peroneal nerve 100 -0.217 -2.197 0.031
hbA1c and peroneal nerve distal latency 100 -0.346 -3.648 0.000
hbA1c and amplitude of peroneal nerve 
evoked muscale response 100 -0.233 -2.372 0.010
hbA1c and CmAP of peroneal nerve 100 -0.242 -2.465 0.015
hbA1c and mnCV of tibial nerve 100 -0.239 -2.439 0.016
hbA1c and tibial nerve distal latency 100 -0.260 -2.667 0.000
hbA1c and amplitude of tibial nerve evoked 
muscale response 100 -0.228 -2.319 0.022
hbA1c and CmAP of tibial nerve 100 -0.246 -2.508 0.014
hbA1c and f-wave in arms 100 0.222 2.251 0.027
hbA1c and f-wave in legs 100 0.300 3.115 0.002
hbA1c and SnCV of ulnar nerve 100 -0.337 -3.548 0.000
hbA1c and amplitude of  ulnar nerve evoked 
sensory potential 100 -0.217 -2.203 0.020
hbA1c and SnCV of sural nerve 100 -0.245 -2.498 0.014
mnCV = motor nerve conduction velocity; SnCV = sensory nerve conduction velocity; CmAP = compound motor action 
potential; P<0.05
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ness was the leading symptom23. The most prominent 
clinical sensory symptom in our patients was pain re-
sembling electric shock. The vibration disorder in legs 
is the sign of such neuropathy in which ulcerations 
in legs will appear soon, and which is the most im-
portant clinical sign according to Kanji et al.24. The 
vibration disorder in legs was experienced by 81% of 
our patients, while young et al. demonstrated this 
disorder to show positive correlation with the scale 
of neurologic disorders in patients with diabetic poly-
neuropathy25. de Wytt et al. recommend the use 
of neurographic methods as the “gold standard” to 
specify the diagnosis19, whereas liu et al. claim that 
electrophysiological changes do not always correlate 
with the clinical signs of polyneuropathy26. Said et al. 
(2008) conclude that detection of pain and sense and 
temperature disorders is the best method for its detec-
tion, since non-myelinated fibers sustain damage ear-
lier, whereas motor deficiency, which can be detected 
by clinical examination and emng testing, appears 
later27. Since early detection of the sense disorder and 
pain is not easy in practice, it is more acceptable for 
us to apply the experiences reported by Karsidag et 
al. (2005), which confirm that testing of electrophysi-
ological parameters is very reliable in the detection of 
early neuropathy, even in patients with stable neuro-
logic status17.
in a study published at the beginning of 2010, the 
authors report that, in order to specify the diagnosis, 
the sensitivity of vibration sensation testing needs to 
be 86%, the scale of neurologic examination (diabetic 
neuropathy examination, dne) 85%, and the study 
of conduction velocity 71%28. Keeping this in view, 
we consolidated the clinical symptoms, clinical signs 
and electrophysiological parameters when evaluating 
our patients and concluded that it was the most con-
vincing way of early detection of polyneuropathy and 
evaluation of its severity.
Although the course of diabetes is rather indi-
vidual and depends on different disease control fac-
tors, hereditary factors and environmental influences, 
de block et al. conclude, based on the research of the 
factors possibly influencing diabetic neuropathy and 
retinopathy, that the duration of diabetes and hbA1c 
are the most important and most influential ones29. 
Our study was directed towards finding the symp-
toms, signs and electrophysiological parameters of 
polyneuropathy that are influenced by these measur-
able factors: hbA1c and duration of diabetes. Patients 
with longer duration of dm had a greater number of 
sensory disorders; they had more often the feeling of 
feet hypersensitivity generated by damage to thick 
myelinated fibers that transfer the sense of vibrations. 
The duration of disease also influences the neuropathy 
pain to appear more often, thus lowering the patient 
quality of life30. All clinical signs of polyneuropathy 
appear more often in patients with longer dm dura-
tion; they develop weakness in legs and arms more 
often, their walk is unstable, and the emng testing 
reveals severe loss of peripheral motoneurons due to 
axon damage, as well as the reduced conduction ve-
locity of the peripheral motor and sensory nerves due 
















mnCV of ulnar nerve (m/s) 59.13±4.48 51.47±7.53 50.9±7.74 0.04
SnCV of ulnar nerve (m/s) 36.41±9.24 34.60±8.23 30.44±7.21 0.03
SnCV of sural nerve (m/s) 39.45±3.28 34.09±11.50 29.74±9.74 0.02
f-wave in arms (ms) 27.61±1.66 28.43±2.81 30.56±3.83 0.02
f-wave in legs (ms) 40.91±21.44 50.68±3.06 54.86±11.9 0.01
total patients n=100 6 16 78
mnCV = motor nerve conduction velocity; SnCV = sensory nerve conduction velocity; P<0.05
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to the loss of myelin. it appears that, in patients with 
dm, polyneuropathy will appear sooner that retin-
opathy. According to de block et al., the patients who 
develop diabetic complications in terms of retinopa-
thy have been suffering from dm for 25 years on an 
average29. On the other hand, our patients with mild 
polyneuropathy had suffered from dm for 8 years on 
an average, and those with severe neuropathy for 16 
years. besides, retinopathy is to appear less frequently 
than polyneuropathy. According to a study conducted 
in Sweden, retinopathy developed in 29% and neu-
ropathy in 67% of 156 patients suffering from type 2 
dm for 7 years on an average31. 
in our patients, the values of hbA1c showed no sta-
tistically significant correlation with the significance 
and frequency of sensory symptoms, and nearly no cor-
relation with the occurrence of clinical signs of poly-
neuropathy. Only the lower or absent sense of vibration 
correlated significantly with the higher values of hbA1c 
in 88% of the patients with poorly regulated glycemia. 
A study from 1998 showed the severity of diabetic 
polyneuropathy to be related to poor glycemia control, 
having in mind that the hbA1c cut-off value discrimi-
nating good and poor glycemia control was set to less or 
more than 9%32. in our study, the higher levels of gly-
cemia determined by hbA1c influenced the reduction 
of conduction velocity of all the measured motor and 
sensory fibers in legs, and they worsened other electro-
physiological parameters in legs (f wave latency, dis-
tal latency, etc.). reports of prominent denervation on 
emg in patients with higher levels of hbA1c show that 
not only the myelin of peripheral nerves was damaged, 
but there was also axonal damage. in our categories of 
patients with acceptably and poorly regulated hbA1c, 
we observed a statistically significant worsening of the 
f wave latency and conduction velocity of sensory fi-
bers in arms and legs as compared to patients with well-
regulated hbA1c. This proves that these are the most 
sensitive electrophysiological indicators of the effect of 
glycemia regulation on the severity of polyneuropathy 
and therefore very convenient for its monitoring. This is 
consistent with other authors who emphasize the value 
of f wave and conduction velocity of sensory nerves in 
diagnosing and monitoring the progression of polyneu-
ropathy in patients with dm21,33.
in conclusion, the higher values of glycemia deter-
mined by hbA1c are a significant predictor of electro-
physiological changes of peripheral nerves in case of 
diabetic polyneuropathy, and the longer presence of 
type 2 dm is the most convincing factor that, besides 
causing worsening of electrophysiological parameters 
in peripheral nerves, it also contributes to greater 
prominence of uncomfortable sensory symptoms and 
disabling clinical signs. 
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Sažetak
KliničKi i eleKtrOfiZiOlOšKi ZnACi diJAbetične POlineurOPAtiJe 
– utJeCAJ gliKemiJe i trAJAnJA šećerne bOleSti
B. Kovač, B. Kovač, S. Marušić-Emedi, S. Svalina i V. Demarin
dijabetična polineuropatija javlja se u oko 50% bolesnika s dijabetesom. njezin patofiziološki mehanizam nastanka 
nije u potpunosti razjašnjen, a glavna zbivanja svode se na promjenu neuralnog fenotipa i vasa nervorum. Kako postoje 
mnogi dokazi o neurotoksičnosti glukoze, cilj studije bio je ispitati utjecaj glikemije na težinu dijabetične polineuropatije. 
budući da neka iskustva u praksi upućuju na prisutnost teških komplikacija u bolesnika koji imaju dijabetes kraćeg tra-
janja, ispitao se utjecaj dužine trajanja dijabetesa na težinu pridružene neuropatije. Klinički i elektromioneurografski je 
ispitano 100 bolesnika s dijabetičnom polineuropatijom. uvjet je bio da bolesnici nemaju laboratorijske znakove bubrežnog 
oštećenja, a analizirao se utjecaj vrijednosti hbA1c i trajanja bolesti na kliničke simptome, znakove i elektrofiziološke po-
kazatelje polineuropatije. rezultati su pokazali da 78% bolesnika s dijabetičnom polineuropatijom nema dobro reguliranu 
glikemiju. trajanje dijabetesa utječe na pojavu većeg broja senzornih simptoma, od kojih se osjećaj boli poput udara struje 
javlja u 63% bolesnika, a utječe i na pogoršanje brzine provodljivosti senzornih i motornih živaca. hbA1c utječe na čitav niz 
elektrofizioloških pokazatelja dijabetične polineuropatije.
Ključne riječi: Dijabetes melitus; Hemoglobin glikozilirani A1c; Simptomi i znakovi; Dijabetična neuropatija; Elektromio-
grafija

